Search Results for "vasodilators"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for vasodilators. Results 11 to 15 of 15 total matches.
Comparison Chart: Some Drugs for HFrEF
The Medical Letter on Drugs and Therapeutics • May 26, 2025 (Issue 1729)
vasoactive peptides, enhances vasodilation and sodium excretion
. Dose should be doubled every 2 weeks ...
View the Comparison Chart: Some Drugs for HFrEF
Med Lett Drugs Ther. 2025 May 26;67(1729):e1-15 doi:10.58347/tml.2025.1729b | Show Introduction Hide Introduction
Zavegepant (Zavzpret) for Acute Treatment of Migraine
The Medical Letter on Drugs and Therapeutics • Jul 24, 2023 (Issue 1681)
PHARMACOLOGY ― CGRP, a potent vasodilator and
neurotransmitter found in the trigeminal nerve and
spinal ...
The FDA has approved zavegepant nasal spray
(Zavzpret – Pfizer) for acute treatment of migraine
with or without aura in adults. Zavzpret is the first
nasal spray formulation of a calcitonin gene-related
peptide (CGRP) receptor antagonist ("gepant") to
become available in the US.
Med Lett Drugs Ther. 2023 Jul 24;65(1681):116-8 doi:10.58347/tml.2023.1681c | Show Introduction Hide Introduction
Atogepant (Qulipta) for Migraine Prevention
The Medical Letter on Drugs and Therapeutics • Nov 01, 2021 (Issue 1636)
the onset of menses.3
MECHANISM OF ACTION — CGRP is a potent
vasodilator and pain-signaling ...
Atogepant (Qulipta – Abbvie), an oral small-molecule
calcitonin gene-related peptide (CGRP) receptor
antagonist ("gepant"), has been approved by the
FDA for prevention of episodic migraine in adults. It
is the second oral CGRP receptor antagonist to be
approved in the US for this indication; the first was
rimegepant (Nurtec ODT), which is also approved
for acute treatment of migraine. Parenteral CGRP
monoclonal antibodies are approved for prevention
of migraine (see Table 3).
Drugs for Chronic Heart Failure
The Medical Letter on Drugs and Therapeutics • May 26, 2025 (Issue 1729)
– generic 5, 10, 20, 100 mg tabs 10-20 mg once/day 200 mg once/day or 41.80
in divided doses
Vasodilators ...
Pharmacologic management of chronic heart failure
(HF) is primarily determined by the patient's left
ventricular ejection fraction (LVEF) and severity of
symptoms. Patients with chronic HF who have an
LVEF ≤40% are considered to have heart failure with
reduced ejection fraction (HFrEF) and those with an
LVEF ≥50% are considered to have heart failure with
preserved ejection fraction (HFpEF). Patients with an
LVEF of 41-49% have heart failure with mildly reduced
or mid-range ejection fraction.
Med Lett Drugs Ther. 2025 May 26;67(1729):81-8 doi:10.58347/tml.2025.1729a | Show Introduction Hide Introduction
Drugs for Benign Prostatic Hyperplasia
The Medical Letter on Drugs and Therapeutics • May 02, 2022 (Issue 1649)
additive vasodilation leading
to orthostasis. Strong CYP3A4 inhibitors such as
ketoconazole can increase ...
About 60% of men ≥60 years old have clinically
relevant prostatic enlargement due to benign prostatic
hyperplasia (BPH). The goals of treatment are to
decrease lower urinary tract symptoms and to prevent
disease progression and complications such as acute
urinary retention. The American Urologic Association's
guidelines for treatment of BPH were recently updated.